Chemotherapy of Leishmaniasis.
Annual rept. no. 7, 1 Jan-31 Dec 81,
GEORGIA UNIV ATHENS
Pagination or Media Count:
Three-day infections of Leishmania donovani in the golden hamster primary visceral test system were used to test a total of 292 compounds 281 new compounds and 11 compounds requiring additional testing for antileishmanial activity against visceral leishmaniasis and 19 day infections of Lieshmania braziliensis panamensis in the golden hamster primary cutaneous test system were used to test a total of 226 different compounds for activity against cutaneous infections. One hundred and nineteen of the 292 compounds tested in the primary visceral test system were observed to have significant suppressive activity against L. donovani at one or more drug dosage levels. A total of twenty-two of these compounds had sufficient antileishmanial activity to warrant the calculation of a Glucantime Index. Eighty-one of the 226 compounds tested in the primary cutaneous test system were noted to have significant suppressive activity against L. braziliensis panamensis at one or more drug dosage levels. A total of ten of these had antileishmanial activity sufficient for the calculation of a Glucantime Index. Preliminary studies of liposome-encapsulated Glucantime for suppressive activity against lesions of L. braziliensis panamensis indicated little or no enhancement of the activity of this drug against this parasite when compared to Glucantime in the absence of liposomes.
- Medicine and Medical Research